4.7 Article

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation

期刊

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2020-001223

关键词

biomarkers; tumor; immunity; cellular; immunoassay; myeloid-derived suppressor cells; head and neck neoplasms

资金

  1. European Cooperation in Science and Technology (COST) Action Mye--EUNITER [BM1404]
  2. Deutsche Forschungsgemeinschaft (DFG) [BR 2278/6-1]
  3. Wellcome Trust [101067/Z/13/Z]
  4. MRC Centre\ grant [MR/N022556/1]
  5. STOPbraintumors Foundation
  6. COST (European Union)
  7. Dutch Cancer Society [KUN2015-7604, KWF11266]
  8. German Research Council [RTG2099/2]
  9. Serbian Ministry of Education, Science and Technological Development [451-03-68/2020-14/200015]
  10. Scientific and Technological Research Council of Turkey, (TUBITAK) [115S636]
  11. European Cooperation in Science and Technology (COST--EU) Action [BM1404]
  12. European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programmeprogram [715048]
  13. Pasteur Paris University International PhD program
  14. Institut Carnot Microbes et Sante
  15. Sidaction
  16. FEDER through Programa Operacional Regional de Lisboa, do PORTUGAL 2020 [PTDC/MED--IMU/30474/2017, LISBOA-01-0145--FEDER-030474]
  17. Fundacao para a Ciencia e a Tecnologia
  18. Gilead Genesis
  19. Polish National Science Center [UMO-2011/02/A/NZ5/00337, UMO-2017/25/B/NZ6/01003]
  20. Swedish Research Council [2019-01036]
  21. Faculty of Engineering and Natural Sciences, Western Norway University of Applied Sciences, Norway
  22. MRC [MR/N022556/1] Funding Source: UKRI

向作者/读者索取更多资源

Background Myeloid-derived suppressor cells (MDSC) are a functional myeloid cell subset that includes myeloid cells with immune suppressive properties. The presence of MDSC has been reported in the peripheral blood of patients with several malignant and non-malignant diseases. So far, direct comparison of MDSC across different diseases and Centers is hindered by technical pitfalls and a lack of standardized methodology. To overcome this issue, we formed a network through the COST Action Mye-EUNITER () with the goal to standardize and facilitate the comparative analysis of human circulating MDSC in cancer, inflammation and infection. In this manuscript, we present the results of the multicenter study Mye-EUNITER MDSC Monitoring Initiative, that involved 13 laboratories and compared circulating MDSC subsets across multiple diseases, using a common protocol for the isolation, identification and characterization of these cells. Methods We developed, tested, executed and optimized a standard operating procedure for the isolation and immunophenotyping of MDSC using blood from healthy donors. We applied this procedure to the blood of almost 400 patients and controls with different solid tumors and non-malignant diseases. The latter included viral infections such as HIV and hepatitis B virus, but also psoriasis and cardiovascular disorders. Results We observed that the frequency of MDSC in healthy donors varied substantially between centers and was influenced by technical aspects such as the anticoagulant and separation method used. Expansion of polymorphonuclear (PMN)-MDSC exceeded the expansion of monocytic MDSC (M-MDSC) in five out of six solid tumors. PMN-MDSC expansion was more pronounced in cancer compared with infection and inflammation. Programmed death-ligand 1 was primarily expressed in M-MDSC and e-MDSC and was not upregulated as a consequence of disease. LOX-1 expression was confined to PMN-MDSC. Conclusions This study provides improved technical protocols and workflows for the multi-center analysis of circulating human MDSC subsets. Application of these workflows revealed a predominant expansion of PMN-MDSC in solid tumors that exceeds expansion in chronic infection and inflammation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据